| Followers | 40 |
| Posts | 5751 |
| Boards Moderated | 0 |
| Alias Born | 04/12/2021 |
Monday, August 29, 2022 7:53:26 AM
Adding up all the shares from each entity mentioned in the form 13 collectively, since all the entities appear to be interconnected and on the same side of the legal dispute, is still about 37.5 percent of 56 million in my estimation,
The below page lists Zours as current chairman of BFRI:
https://people.equilar.com/bio/wilhelm-zours-biofrontera-ag/33831858
The company could clarify:
Who is in control of the company and by what method was the OS increased.
The below page lists Zours as current chairman of BFRI:
https://people.equilar.com/bio/wilhelm-zours-biofrontera-ag/33831858
The company could clarify:
Who is in control of the company and by what method was the OS increased.
my posts are always theory and not financial advice
Recent BFRI News
- Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/19/2026 01:25:00 PM
- Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 • GlobeNewswire Inc. • 03/09/2026 09:25:00 PM
- Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris • GlobeNewswire Inc. • 03/09/2026 01:15:00 PM
- U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable • GlobeNewswire Inc. • 02/26/2026 02:15:00 PM
- Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities • GlobeNewswire Inc. • 02/17/2026 02:15:00 PM
- Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma • GlobeNewswire Inc. • 02/11/2026 02:15:00 PM
- Biofrontera Reports Positive Phase 3 Data for Ameluz in Actinic Keratosis • IH Market News • 02/09/2026 02:39:24 PM
- Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint • GlobeNewswire Inc. • 02/09/2026 02:15:00 PM
- Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth • GlobeNewswire Inc. • 01/13/2026 01:30:00 PM
- Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones • GlobeNewswire Inc. • 01/08/2026 01:45:00 PM
- Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio • GlobeNewswire Inc. • 12/18/2025 01:45:00 PM
- Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities • GlobeNewswire Inc. • 12/04/2025 02:00:00 PM
- Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT • GlobeNewswire Inc. • 12/02/2025 01:45:00 PM
- Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 11/13/2025 01:15:00 PM
- Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M • GlobeNewswire Inc. • 11/07/2025 01:00:00 PM
- Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025 • GlobeNewswire Inc. • 11/06/2025 09:01:00 PM
- Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG • GlobeNewswire Inc. • 10/23/2025 12:45:00 PM
- Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 • GlobeNewswire Inc. • 09/26/2025 01:15:00 PM
- Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program • GlobeNewswire Inc. • 09/23/2025 01:20:00 PM
- Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk • GlobeNewswire Inc. • 09/16/2025 02:30:00 PM
- Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris • GlobeNewswire Inc. • 08/25/2025 12:25:00 PM
- Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 08/13/2025 09:20:00 PM
- Biofrontera Inc. Appoints George Jones as Chief Commercial Officer • GlobeNewswire Inc. • 08/11/2025 08:25:00 PM
- Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 • GlobeNewswire Inc. • 08/04/2025 06:00:00 PM
- Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment • GlobeNewswire Inc. • 06/30/2025 12:00:00 PM
